A milestone year with momentum continuing to build.
Since the inception of Cogstate in 1999, our investment thesis has been focused on an aging population, an increasing incidence of Alzheimer’s disease and the need to provide technology solutions that simplify the measurement of cognition for patients, their doctors and the companies developing new and better therapies. Throughout that long journey, we have remained steadfast in our belief that, eventually, treatment options for Alzheimer’s disease would come to market and, when they did, Cogstate would be there to provide technology solutions that make cognitive assessment easy and accessible.
Our goal has always been to play a small but important role in delivering better brain health to all.
Within the context of our original ambitions, the 2021 financial year has been a watershed year for Cogstate.
(all figures in US$)
Please fill out the form to subscribe